Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Melanoma 16Brenner Tumor 16Stomach Neoplasms 15Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 13Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Colorectal Neoplasms 7Adenocarcinoma 7

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2sintilimab 1nimotuzumab 1avelumab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Hydroxychloroquine 1Fluorouracil 1Capecitabine 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Cancer Resectable × Taxes × Clear all
NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting
381 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡